News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Cellegy Pharmaceuticals (CLGY) Appoints Agis To Distribute Rectogesic(R) In Israel

6/20/2006 12:15:16 PM

HUNTINGDON VALLEY, Penn., June 20 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. announced today that it has appointed Agis Commercial Agencies Ltd. as its exclusive distributor for Rectogesic(R) nitroglycerin ointment in Israel. Agis will file for regulatory approval utilizing the European Common Technical Document that provided the basis for approval of Rectogesic by 20 European countries earlier this year.

Agis, which was acquired by Perrigo last year, is a diversified pharmaceutical company with operations in the production, import and marketing of major ethical drugs in Israel. The company manufactures under license and also imports pharmaceuticals, representing several major pharmaceutical companies in Israel, including: Schering AG, Bayer Diagnostics, Solvay, and Bayer AG.

"We are pleased to bring Rectogesic to market in Israel through a partnership with Agis," said Richard C. Williams, Cellegy's Chairman and interim CEO. "Israeli clinical investigators played a significant role in the trials that led to approval for Rectogesic in Europe, and we wanted to find the right distributor to bring the product to market. Rectogesic fits well with the target audience currently called on by Agis, and both Agis and Cellegy expect rapid commercial uptake of the product."

Rectogesic ointment, 0.4% is currently being sold by ProStrakan Ltd., Cellegy's licensee in Europe, for the treatment of anal fissure. The product was launched in the UK during the second quarter of 2005 and through the Mutual Recognition Process, is now approved in 20 countries in Europe. Sales continue to exceed expectations.

About Cellegy

Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction, HIV prevention and gastrointestinal disorders. Savvy(R) (C31G vaginal gel), a novel microbicide gel product for contraception and the reduction in transmission of HIV in women, is currently undergoing Phase 3 clinical studies in the United States and Africa.

Forward Looking Statements

This press release contains forward-looking statements. Investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties relate to, among other factors: market acceptance and the level of future sales of Rectogesic in Israel and Europe; the timing and outcome of FDA action following the Advisory Committee's review and recommendation concerning the Company's Cellegesic product; completion, timing and outcome of clinical trials, including primarily the Savvy prevention and contraceptive Phase 3 studies; and the need and ability to complete corporate partnerships and additional financings. For more information regarding risk factors, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other filings with the Securities and Exchange Commission.

Cellegy Pharmaceuticals, Inc.

CONTACT: Richard C. Williams, Chairman and Interim CEO, +1-650-616-2200,or Robert J. Caso, Vice President, Finance & CFO, +1-215-914-0900, Ext.603, both of Cellegy Pharmaceuticals, Inc.

Read at

Related News

comments powered by Disqus